MannKind Corporation (NASDAQ: MNKD) will report its second quarter 2026 financial results after market close on Wednesday, August 5, 2026. This filing serves as a procedural notice for investors awaiting the company’s latest performance metrics in the biopharmaceutical sector. The announcement confirms the timeline for the disclosure of key financial data, allowing stakeholders to prepare for the upcoming earnings review.

The company’s management team will host a conference call at 4:30 p.m. Eastern Time to review the financial results and provide a business update. This session offers investors direct access to executive commentary regarding operational performance and strategic developments. The event underscores the company’s commitment to transparent communication with its shareholder base during critical reporting periods.

Webcast Access and Replay

The webcast of the conference call will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations . Investors unable to attend the live broadcast can access a replay in the same location within 24 hours following the call. The archived recording will remain accessible for approximately 90 days, ensuring broad availability for analysis and review.

Company Profile

MannKind Corporation is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, the company develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.

What the Numbers Show

As this article covers a pre-earnings announcement, no financial metrics are currently available for analysis. The significance of this notice lies in its confirmation of the reporting schedule rather than any disclosed performance data. Investors should monitor the upcoming results for insights into revenue trends, margin stability, and progress in commercializing its portfolio of treatments for cardiometabolic and orphan lung conditions.

MannKind Corporation has been awarded a grant by Breakthrough T1D to support the ongoing INHALE-1ST clinical study, which evaluates the initiation of Afrezza Inhalation Powder shortly after a type 1 diabetes diagnosis in pediatric patients. This financial backing underscores the importance of advancing new therapeutic options for pediatric diabetes care and strengthens efforts to bring innovation to this patient population. The grant was provided through Breakthrough T1D's Industry Discovery and Development Partnership (IDDP) program.

The INHALE-1ST study is a multi-center clinical trial designed to assess the safety and efficacy of Afrezza used in combination with subcutaneously injected basal insulin once-daily. The trial focuses on youth aged 10 to <18 years who have been newly diagnosed with type 1 diabetes. This initiative builds on the recent FDA approval of inhaled insulin for use in pediatric patients aged 6 and older. MannKind recently completed enrollment of the pilot phase of the trial.

Strategic Support and Objectives

Breakthrough T1D, formerly JDRF, is a leading global type 1 diabetes research and advocacy organization. The strategic support from this entity reinforces the significance of addressing unmet needs in pediatric diabetes care through the development of inhaled insulin therapies. Michael Castagna, Chief Executive Officer of MannKind Corporation, stated that the collaboration represents meaningful external support of Afrezza’s potential role in transforming insulin therapy.

Study Details

The single-arm study will follow participants for 13 weeks during the main phase, followed by an optional extension phase for up to 26 weeks. The primary endpoint is the percentage of participants with a continuous glucose monitor who measured time-in-range of 70-180 mg/dL ≥70% during 14 days prior to the 13-week visit.